Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Reading

Showing results (361-370 of 374) with videos related to

Pageof 38
Sort By:
Ebiomedicine|October 21, 2023
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Nature Communications|November 11, 2018
MAIT cells contribute to protection against lethal influenza infection in vivoBonnie van Wilgenburg, Liyen Loh, Zhenjun Chen, et al.
Radiology|November 24, 2005
Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statementMary C Frates, Carol B Benson, J William Charboneau, et al.
Ultrasound Quarterly|December 6, 2006
Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statementMary C Frates, Carol B Benson, J William Charboneau, et al.
The EMBO Journal|February 10, 2023
Immunity against Moraxella catarrhalis requires guanylate-binding proteins and caspase-11-NLRP3 inflammasomesDaniel Enosi Tuipulotu, Shouya Feng, Abhimanu Pandey, et al.
The Journal of Infectious Diseases|November 24, 2025
Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Trials|January 24, 2018
Overnight auto-adjusting continuous airway pressure + standard care compared with standard care alone in the prevention of morbidity in sickle cell disease phase II (POMS2b): study protocol for a randomised controlled trialJo Howard, April E Slee, Simon Skene, et al.
Nature Structural & Molecular Biology|July 8, 2025
A nanobody-based therapeutic targeting Nipah virus limits viral escapeAriel Isaacs, Guillermo Valenzuela Nieto, Xinghai Zhang, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Zheyi Li, et al.
Clinical & Translational Immunology|April 12, 2021
Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2Daniel Watterson, Danushka K Wijesundara, Naphak Modhiran, et al.
Pageof 38

Showing results (361-370 of 374) with videos related to

Sort By:
Pageof 38
Ebiomedicine|October 21, 2023
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Nature Communications|November 11, 2018
MAIT cells contribute to protection against lethal influenza infection in vivoBonnie van Wilgenburg, Liyen Loh, Zhenjun Chen, et al.
Radiology|November 24, 2005
Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statementMary C Frates, Carol B Benson, J William Charboneau, et al.
Ultrasound Quarterly|December 6, 2006
Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statementMary C Frates, Carol B Benson, J William Charboneau, et al.
The EMBO Journal|February 10, 2023
Immunity against Moraxella catarrhalis requires guanylate-binding proteins and caspase-11-NLRP3 inflammasomesDaniel Enosi Tuipulotu, Shouya Feng, Abhimanu Pandey, et al.
The Journal of Infectious Diseases|November 24, 2025
Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Trials|January 24, 2018
Overnight auto-adjusting continuous airway pressure + standard care compared with standard care alone in the prevention of morbidity in sickle cell disease phase II (POMS2b): study protocol for a randomised controlled trialJo Howard, April E Slee, Simon Skene, et al.
Nature Structural & Molecular Biology|July 8, 2025
A nanobody-based therapeutic targeting Nipah virus limits viral escapeAriel Isaacs, Guillermo Valenzuela Nieto, Xinghai Zhang, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Zheyi Li, et al.
Clinical & Translational Immunology|April 12, 2021
Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2Daniel Watterson, Danushka K Wijesundara, Naphak Modhiran, et al.
Pageof 38